Norman Zaffater, MD
Ophthalmology · Bossier City, LANPI 1124010939
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,033 of the $5,820 with a category attached, or 86.5%. 19 manufacturers reported payments, led by Biotissue Holdings Inc. at 38.5% of the total. 2025 is the largest year on record at $2,794, 7.9 times the $353 reported in 2019.
Across 144 payments — averaging $40.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Alcon$1K
- AbbVie$565
- Heru, Inc.$407
- Novartis$269
- Rxsight Inc$211
- plus $1K from 13 others
What the payments were for
- Travel & lodging$78714%
- Food & beverage$5,03386%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 26 | $2,240 |
| Alcon | 35 | $1,067 |
| AbbVie(2 entities) | 19 | $565 |
| Heru, Inc. | 2 | $407 |
| Novartis | 11 | $269 |
| Rxsight Inc | 4 | $211 |
| Amgen(2 entities) | 9 | $200 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $155 |
| Oyster Point Pharma, Inc. | 5 | $131 |
| Tarsus Pharmaceuticals, Inc. | 6 | $127 |
| Sight Sciences, Inc. | 5 | $115 |
| Bausch & Lomb Americas Inc. | 4 | $98 |
| Ocular Therapeutix, Inc. | 3 | $69 |
| Kala Pharmaceuticals, Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
| NEW World Medical,inc. | 1 | $16 |
| Carl Zeiss Meditec USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$471
- Heru HMD$407
- AmnioGraft$150
- AcrySof IQ VIVITY IOL$140
- ReSTOR$125
- DURYSTA$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$117
- ARGOS$114
How this compares
$5,820 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 20 | $37,635 |
| RestasisCyclosporine | 26 | $24,518 |
| XiidraLifitegrast | 23 | $20,875 |
| ProlensaBromfenac Sodium | 18 | $6,307 |
| Cyclosporine | 11 | $4,628 |
| Bromfenac Sodium | 26 | $3,922 |
| TobradexTobramycin/Dexamethasone | 15 | $3,919 |
| Prednisolone Acetate | 115 | $3,333 |
| Loteprednol Etabonate | 15 | $2,059 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,255 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 18 | $742 |
| Brimonidine Tartrate | 32 | $705 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $670 |
| Ketorolac Tromethamine | 25 | $595 |
| Latanoprost | 90 | $558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $127 | $37,63520 claims |
| AbbVieRestasis | $565 | $24,51826 claims |
| Bausch & Lomb Americas Inc.Xiidra | $98 | $20,87523 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $20 | $8,36633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Bossier City
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Arthur DelahoussayeHouma$26K
- Michael RedmondAlexandria$24K
- Eric ReishAlexandria$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.